GLP-1 drugs linked to lower macular degeneration risk in a 157,880-patient analysis

A study published in Diabetes, Obesity and Metabolism on May 25, 2026, found that older adults with obesity who started a GLP-1 receptor agonist had a lower rate of newly diagnosed age-related macular degeneration (AMD) compared with people who started other weight-loss medications ^[1]. The finding comes from a "target trial emulation," a method that uses real-world health records to mimic the design of a randomized trial ^[1].

Researchers used the TriNetX global health records network, covering January 2014 through June 2025, and included adults age 60 or older who had obesity but not diabetes ^[1]. They compared people newly starting a GLP-1 receptor agonist with people newly starting other weight-loss drugs, then matched the two groups 1:1 on many characteristics, producing 157,880 matched patients, or 78,940 per group ^[1]. Over a follow-up period of up to seven years, GLP-1 use was linked to a 18% lower risk of developing AMD, with a hazard ratio of 0.82 and a 95% confidence interval of 0.68 to 0.98 ^[1].

When researchers broke the results down by AMD subtype, the drop in risk was statistically significant for "unspecified" AMD cases, with a hazard ratio of 0.70 (95% CI 0.52–0.93) ^[1]. For nonexudative, or "dry," AMD, there was a trend toward lower risk, with a hazard ratio of 0.78, but the confidence interval just touched 1.00 and the p-value was exactly 0.050, meaning the result sits right at the usual cutoff for statistical significance ^[1]. Subgroup analyses hinted that the effect was stronger in women and in adults ages 60 to 69, but the authors labeled these subgroup findings as exploratory, meaning they need confirmation before drawing firm conclusions ^[1].

One notable wrinkle: people in the GLP-1 group were followed for a median of just 1.11 years, compared with 2.56 years for those on other weight-loss drugs ^[1]. Because AMD develops slowly, often over many years, this mismatch makes it harder to be fully confident that the GLP-1 group's lower risk reflects a real, lasting difference rather than simply less time for the disease to show up on the record. The study also analyzed GLP-1 drugs as one class rather than looking separately at semaglutide (Ozempic, Wegovy, Rybelsus) versus tirzepatide (Mounjaro, Zepbound), so it cannot say whether one drug drives the effect more than another ^[1]. The authors ran several sensitivity checks, including one that excluded tirzepatide and one with a one-year lag between drug starts, according to the study's supplementary materials ^[1].

Why it matters for patients

AMD is a leading cause of permanent vision loss in older adults, and there is currently no cure, only treatments that can slow some forms of it ^[1]. If GLP-1 drugs turn out to genuinely lower AMD risk, that would be a meaningful side benefit for people already taking them for weight or blood sugar management. But this study cannot prove cause and effect. It is an observational analysis of health records, not a randomized clinical trial, and the authors themselves say it remains unclear whether any protective effect comes from a direct action of the drug on the eye, from the weight loss itself, or from some combination of both ^[1]. Patients weighing GLP-1 therapy should know this is one early signal among many considerations, not a proven eye-health treatment.

What happens next

The study's authors call for further mechanistic research and prospective clinical trials to confirm or refute the association ^[1]. No trial dates or names were given in the available materials, so it is not yet known when such confirmatory studies might begin or report results.